AorTx, Inc.

Redwood City, CA

AorTx is developing device solutions that rapidly convert aortic valve replacement from being one of the most severely invasive heart surgical procedures to that of a minimally invasive, percutaneous, approach. AorTx, guided by seasoned medical device engineers and clinicians, is developing devices that cover the entire procedural solution for percutaneous heart valve therapy--from the implant itself to delivery and deployment of the valve. The company was sold to Hansen Medical, Inc. (NASDAQ: HNSN) in December 2007.

Atritech, Inc.

Plymouth, MN

www.atritech.net
Atritech has developed the WATCHMAN®, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby reducing the risk of stroke and eliminating the need for long-term use of blood thinning medications.

Avantis Medical Systems, Inc.

Sunnyvale, CA

www.avantismedical.com
Avantis Medical Systems is a medical device company founded to develop and manufacture catheter-based endoscopic devices. Its initial focus is on devices for use in both detecting and treating cancers of the gastrointestinal (GI) tract.

Axis Surgical Technologies, Inc.

Mountain View, CA

Axis Surgical Technologies, Inc. was founded to develop, manufacture, and market innovative devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Axis offers a powerful, novel integration of visualization and articulation capabilities that will ultimately provide a strong, sustainable competitive advantage in this market. Axis’s technical and management team has a proven record of successful start-up companies and has benefited from a number of successful exits in life sciences companies.

Broncus Technologies, Inc.

Mountain View, CA

www.broncus.com
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population.

Bioabsorbable Therapeutics, Inc.

Menlo Park, CA

www.bioabsorbabletx.com
Bioabsorbable Therapeutics (BTI) is developing the next generation of medical devices for treating vascular disease. BTI utilizes novel, proprietary anti-inflammatory polymers to create fully bioabsorbable coatings and stents. BTI has development projects for both coronary vascular disease and peripheral vascular disease.

CV Ingenuity Corp

Atherton, CA

CV Ingenuity Corp. is developing drug-eluting balloon platform technology for cardiac and peripheral arteries.

Devax, Inc.

Irvine, CA

www.devax.net
Devax is a medical device company engaged in the development of a proprietary drug eluting stent system that provides a clinical solution to treat coronary, carotid and peripheral vascular bifurcation lesions.

Embrella Cardiovascular, Inc.

Malvern, PA

www.embrella.net
Embrella Cardiovascular is dedicated to creating a new standard-of-care for cerebral embolic protection during cardiovascular procedures. The company believes that this technology can be successfully utilized as a safe, efficient, and cost effective method of preventing clot or debris from embolizing into the cerebral circulation during cardiovascular procedures.

Guided Delivery Systems, Inc.

Santa Clara, CA

www.gdsmed.com
Guided Delivery Systems (GDS) is a leader in developing percutaneous trans-catheter mitral annuloplasty systems for the treatment of mitral regurgitation associated with Congestive Heart Failure.

Hotspur Technologies, Inc.

Mountain View, CA

Hotspur Technologies, Inc. is developing percutaneous product solutions designed to address issues associated with hemodialysis access.

Interventional Spine, Inc.

Irvine, CA

www.i-spineinc.com
Interventional Spine (previously Triage Medical) is a unique medical device company focused on the design, development and marketing of patented percutaneous systems to treat lower back pain. Products are intended to bridge the therapeutic continuum of conservative treatment for chronic pain to complex open surgery for debilitating pain.

MiCardia, Inc.

Irvine, CA

www.micardia.com
MiCardia is a developmental stage company combining metallurgical and polymeric sciences expertise with biomedical engineering to develop minimally-invasive devices for interventional cardiology and cardiac surgery. MiCardia has combined extensive technical engineering background with in-depth experience in the creation and design of novel device solutions for new therapies focused on the treatment of Congestive Heart Failure ("CHF").

Nellix Endovascular, Inc.

Palo Alto, CA

www.nellix.com
Nellix has developed a revolutionary, percutaneously deliverable endograft for the treatment of Abdominal Aortic Aneurysms and Thoracic Aortic Aneurysms. This aortic endograft device and treatment fills the aneurysm, providing a highly stable and durable seal. The novel technology enables treatment of all aortic aneurysms and provides a distinct advantage over current therapies.

Onset Medical Corporation

Santa Monica, CA

www.onsetmedical.com
Onset Medical engages in the development, manufacturing and marketing of percutaneous and minimally-invasive access devices to extend the diagnostic and therapeutic “reach” of surgeons and interventionalists with patented technology that provides guided and controlled deployment of sheath catheters.

ReVascular Therapeutics, Inc.

Sunnyvale, CA

www.revascular.com
ReVascular Therapeutics has pioneered advances in technology for the intravascular treatment of complex lesions and total occlusions that typically cannot be treated using current catheter-based technologies and products.

Reverse Medical

Irvine, CA

Reverse Medical is a new BioStar portfolio company that develops innovative neurovascular devices for improving the treatment of stroke patients. Reverse intends to develop devices that will prevent stroke during carotid artery stenting procedures.

Setagon, Inc.

Setagon is a medical device company that has created a “Programmed Elution System” (PES) for targeted delivery of drugs and other biologic substances on stents and other medical devices. The company was sold to a major medical device company in December 2007.

SynergEyes, Inc.

Carlsbad, CA

www.synergeyes.com
SynergEyes develops and manufactures hybrid contact lenses that combine the superior visual acuity of a rigid gas permeable lens with the comfort of a soft contact lens. The revolutionary SynergEyes® hybrid contact lens provides the best of both worlds - a stable, high oxygen permeable rigid center that delivers consistent, crisp, clear vision while the outer skirt provides all the all-day comfort of a soft lens.

TriVentures II Fund, LP

Herzelia, Israel

TriVentures II is a venture capital fund formed to identify leading Israeli medical device opportunities, incubate them with syndicated capital and transition them to the US or sell them as non-US entities. TriVentures combines the best of Israel medical innovation with the best of US clinical, business and industrial expertise to create a fast and smooth transition for medical technologies to successful exits.